Mirum Pharmaceuticals, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -10.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.77 | $-0.80 | -3.9% | Miss | |
| Q1 FY26 | $-0.40 | $-0.39 | +2.5% | Beat | Q1 FY26 call |
| Q4 FY25 | not reported | $-0.11 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $0.05 | not reported | not reported | |
| Q2 FY25 | not reported | $-0.12 | not reported | not reported | Q2 FY25 call |
| Q1 FY25 | $-0.39 | $-0.30 | +23.1% | Beat | |
| Q4 FY24 | $-0.27 | $-0.49 | -81.5% | Miss | |
| Q3 FY24 | $-0.45 | $-0.30 | +33.3% | Beat | |
| Q2 FY24 | $-0.48 | $-0.52 | -8.3% | Miss | |
| Q1 FY24 | $-0.40 | $-0.54 | -35.0% | Miss | |
| Q4 FY23 | $-0.34 | $-0.66 | -94.1% | Miss | |
| Q3 FY23 | $-0.64 | $-0.57 | +10.9% | Beat |
Back to MIRM overview · MIRM holders · MIRM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.